ArticleBMC ophthalmology2026
A clinically interpretable deep learning pipeline for diabetic retinopathy classification using EfficientNet, advanced data augmentation and GradCAM.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly and reliable grading of diabetic retinopathy is important for preventing avoidable vision loss. Although deep learning methods have shown strong performance on retinal fundus images, grading remains difficult because of class imbalance, variable image quality, subtle differences between adjacent disease stages, and the need for interpretable predictions. This study developed a clinically interpretable deep learning pipeline for five-class diabetic retinopathy grading.
methodsA classification framework based on EfficientNet-B1 was developed using contrast-limited adaptive histogram equalization for image enhancement, sample-mixing augmentation, focal loss, and test-time augmentation. Model behavior was further examined using calibration analysis, gradient-weighted class activation mapping, and t-distributed stochastic neighbor embedding. The public APTOS 2019 dataset was used. Under the fixed held-out protocol, 2,930 images were used for training, 364 for validation, and 366 for testing. Robustness was further examined using stratified 5-fold cross-validation on a 3,294-image development set with an independent 366-image test set. Performance was summarized using accuracy, macro F1-score, weighted F1-score, average area under the receiver operating characteristic curve, confusion matrices, and calibration error. No formal hypothesis-testing framework was applied.
resultsThe best validation accuracy under the fixed split was 84.07%. On the independent test set, the proposed model achieved 83.61% accuracy without test-time augmentation and 84.97% with test-time augmentation. The average area under the receiver operating characteristic curve was 90.40%. Removing contrast-limited adaptive histogram equalization reduced test accuracy to 80.87%, supporting its contribution to performance. The model showed improved robustness to class imbalance and provided clinically meaningful visual explanations, although Severe diabetic retinopathy remained the most challenging category.
conclusionsThe proposed pipeline achieved competitive benchmark performance for five-class diabetic retinopathy grading and combined classification accuracy with supportive calibration and interpretability analyses. The method appears suitable as a research-stage decision-support approach, but the remaining difficulty in advanced disease grading and the use of a single public dataset indicate that external validation is still required before clinical deployment.
trial registrationThis study used a publicly available benchmark dataset and did not involve a randomized controlled trial or prospective enrollment of human participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.